BCL2 and B-cell chronic lymphocytic leukemia: Interestingly, ruxolitinib causes decreased phosphorylation of pSTAT3Y705 in chronic ibrutinib-resistant CLL and DLBCL cells, resulting in BCL-2 downregulation and sensitization to venetoclax-induced apoptosis (Kapoor, I et al., unpublished).